PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer PatientsTamara L. Lotan, Angelo M. De Marzo|Clinical Cancer Research|2011Cited by 350
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.Edward M. Schaeffer, Deborah A. Freedman-Cass, Tamara L. Lotan et al.|PubMed|2022Cited by 172
Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancerHarsimar Kaur, Tamara L. Lotan|Modern Pathology|2018Cited by 100
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISHTamara L. Lotan, Jeremy A. Squire|Modern Pathology|2016Cited by 90
mTORC1 loss impairs epidermal adhesion via TGF-β/Rho kinase activationKaushal Asrani, Tamara L. Lotan|Journal of Clinical Investigation|2017Cited by 40